Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04790968
Overview
For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery. The surgery involves resection of the prostate and the pelvic lymph nodes. Currently, the most reliable method to confirm lymph node metastases is by histologic examination of the resected lymph nodes. Ideally, one should be able to detect lymph node metastases prior to treatment. Then, the treatment could be better adjusted to each patient. Imaging methods such as prostate specific membrane antigen positron emission tomography (PSMA-PET) can possibly aid the detection of lymph node metastases. In this study, the investigators want to test whether PSMA-PET or a combination of PSMA-PET and MRI (magnetic resonance imaging) can improve staging of lymph nodes before treatment.
Sponsor
Norwegian University of Science and Technology
Phase
N/A
Contacts
Morten Troøyen, MD (STUDY_DIRECTOR)
Øystein Risa, Prof (STUDY_DIRECTOR)
ClinicalTrials.gov
NCT04790968Drug / Compound
Help us improve your experience